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Giant adrenal myelolipoma 
associated with 21-hydroxylase 
deficiency: unusual association 
mimicking an androgen-secreting 
adrenocortical carcinoma
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summaRy
The	 objective	 of	 this	 study	 was	 to	 describe	 a	 case	 of	 giant	 myelolipoma	 associated	 with	
undiagnosed	congenital	adrenal	hyperplasia	 (CAH)	due	 to	21-hydroxylase	 (21OH)	deficiency.	
Five	seven	year-old	male	patient	referred	with	abdominal	ultrasound	revealing	a	left	adrenal	
mass.	Biochemical	investigation	revealed	hyperandrogenism	and	imaging	exams	characterized	
a	 large	 heterogeneous	 left	 adrenal	mass	with	 interweaving	 free	 fat	 tissue,	 compatible	with	
the	diagnosis	 of	myelolipoma,	 and	a	 1.5	 cm	nodule	 in	 the	 right	 adrenal	 gland.	Biochemical	
correlation	has	brought	concerns	about	differential	diagnosis	with	adrenocortical	carcinoma,	
and	 surgical	 excision	 of	 the	 left	 adrenal	 mass	 was	 indicated.	 Anatomopathologic	 findings	
revealed	 a	 myelolipoma	 and	 multinodular	 hyperplasic	 adrenocortex.	 Further	 investigation	
resulted	in	the	diagnosis	of	CAH	due	to	21OH	deficiency.	Concluded	that	CAH	has	been	shown	
to	be	associated	with	adrenocortical	tumors.	Although	rare,	myelolipoma	associated	with	CAH	
should	be	included	in	the	differential	diagnosis	of	adrenal	gland	masses.	Moreover,	CAH	should	
always	 be	 ruled	 out	 in	 incidentally	 detected	 adrenal	masses	 to	 avoid	 unnecessary	 surgical	
procedures.	Arq Bras Endocrinol Metab. 2010;54(4):419-24
sumáRio
O	objetivo	deste	trabalho	foi	descrever	um	caso	de	mielolipoma	gigante	associado	à	hiperpla-
sia	adrenal	congênita	(HAC)	por	deficiência	da	21-hidroxilase	(21OH).	Paciente	do	sexo	mascu-
lino,	57	anos	de	idade,	encaminhado	por	achado	ultrassonográfico	de	massa	adrenal	esquerda.	
Investigação	bioquímica	revelou	hiperandrogenismo	e	exames	de	imagem	revelaram	grande	
lesão	sólida	em	adrenal	esquerda	de	aspecto	heterogêneo,	entremeada	de	tecido	gorduroso,	
compatível	 com	diagnóstico	de	mielolipoma,	e	um	nódulo	de	1,5	cm	na	adrenal	direita.	Os	
achados	bioquímicos	sugeriam	o	diagnóstico	de	carcinoma	adrenocortical,	indicando	cirurgia	
para	retirada	da	massa	adrenal	esquerda.	O	anatomopatológico	confirmou	mielolipoma	e	hi-
perplasia	multinodular	do	córtex	adrenal.	A	investigação	subsequente	diagnosticou	HAC	por	
deficiência	da	21OH.	Concluiu-se	que	a	HAC	 tem	sido	descrita	em	associação	com	 tumores	
adrenocorticais.	Apesar	de	raro,	o	mielolipoma	associado	à	HAC	deve	ser	incluído	nas	possibi-
lidades	diagnósticas	de	massa	adrenal.	Adicionalmente,	a	HAC	deve	ser	sempre	afastada	nos	
casos	de	massa	adrenal	de	achado	incidental,	evitando	cirurgias	desnecessárias.	Arq Bras Endocrinol 
Metab. 2010;54(4):419-24	
clinical case report
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inTRoDucTion
Adrenal myelolipomas are relatively uncommon be-nign tumors, usually small and unilateral. They are 
usually found incidentally and rarely present as giant my-
elolipomas (1). They are composed of mature adipose 
cells and haematopoietic myeloid cells (2,3). Although 
usually asymptomatic, myelolipomas can cause pain upon 
the occurrence of hemorrhage, necrosis or compression. 
Occasionally, they can occur concomitantly with other 
lesions such as cortical adenoma (2-4), ganglioneuroma 
(5), carcinoma (6), pheochromocytoma (7), or CAH 
(8). Although characteristically non-functioning, there 
have been a few reports of myelolipomatous masses as-
sociated with adrenocortical hypersecretion (8,9). On 
radiologic evaluation, they typically present a high fat 
content that gives them a pathognomonic appearance 
on CT and MRI images (10,11). On CT, the presence 
of low attenuation fat in the lesion, which has a density 
of -30 HU, is a specific and diagnostic finding. On MRI, 
the fat components in the lesion demonstrate high sig-
nal on T1- and T2-weighted images and lose signal on 
T1-fat-saturated images resembling intra-abdominal 
fat (10,12). However, the presence of hemorrhage and 
necrosis features can emulate the radiological aspect of 
adrenocortical carcinoma (10).
In this report, we describe an uncommon case of a 
57-year-old man with a giant myelolipoma presented as 
an adrenal mass with a heterogeneous appearance on ra-
diologic evaluation associated with hyperandrogenism 
resulting in preoperative diagnosis of adrenocortical 
carcinoma. The anatomopathologic findings revealed a 
myelolipoma, and further investigation resulted in the 
associated diagnosis of CAH due to 21OH deficiency. 
case RePoRT
A 57-year-old Brazilian male patient was referred to the 
Endocrine Division in June 2008 with abdominal pain 
and an abdominal ultrasound revealing a left adrenal 
mass of 12 x 9 x 12 cm. He was father of two daughters 
aged 32 and 34 years. At admission, the patient wei-
ghed 56.8 kg and was 160 cm tall, with a body mass 
index of 22 kg/m2. He had a blood pressure of 100/70 
mmHg and a heart rate of 72 beats/min. Other phy-
sical examination was unremarkable, except by slightly 
decreased and hard testis (3.5 x 2 cm bilaterally). There 
was no clinical evidence of Cushing’s syndrome, hype-
raldosteronism or pheochromocytoma. A laboratory 
screening for adrenal incidentaloma demonstrated su-
ppressed plasma cortisol levels after 1 mg overnight 
dexamethasone (33 nmol/l; normal < 50); normoka-
lemia (4.3 mmol/L; normal range 3.5-5); normal uri-
nary metanephrines (502 nmol/24h; normal range 31-
1167) and urinary normetanephrines (1147 nmol/24h; 
normal range 240-2459), and plasma catecholamines 
(3.6 nmol/L; normal range 0.7-3.9); normal DHEAS 
(4 mmol/L; normal range 6.5-9.1); normal testostero-
ne (13 nmol/L; normal 8.7-31.2 range), and elevated 
androstenedione (74 nmol/L; normal range 2.1-8.7). 
CT and MRI exams have characterized the lesion as a 
large heterogeneous left adrenal soft tissue mass with 
substantial amount of interweaving free fat tissue. The-
re was also a 1.5 cm nodule with similar features in the 
right adrenal gland (Figure 1). 
Although the imaging features were typical for mye-
lolipoma, the biochemical findings showing androstene-
dione hypersecretion associated with a large adrenal mass 
led to a preoperative diagnosis hypothesis of androgen 
secreting adrenocortical carcinoma. Patient underwent 
open left adrenalectomy. The intraoperatory findings 
demonstrated a 15 x 10 cm left adrenal circumscribed 
mass which was completely excised, and a small pig-
mented right adrenal mass of around 1.5 cm, that was 
not removed due to its benign appearance. Pathological 
findings revealed an enlarged left adrenal gland with a 
yellow and tan circumscribed mass of 15 cm in its lar-
gest diameter that weighed 585 g. At the microscopy 
the tumor was characterized as a myelolipoma that rose 
on a multinodular hyperplasic adrenocortex (Figure 2).
The patient postoperative recovery was unremarka-
ble, but the androgens remained elevated on the fifth 
day after surgery (Table 1). To rule out a potentially 
unsuccessful surgery and to diagnose a suspected CAH, 
measurement of basal and post ACTH1-24 stimulation 
test 17OHP was performed, followed by a 2 mg/day 
dexamethasone suppression test during 5 days. Basal 
17OHP was 261 nmol/L, reaching 342 nmol/L 60 
minutes after ACTH1-24 (Table 1). All androgens sho-
wed a marked suppression after 5 days of the dexame-
thasone suppression test, thus confirming the diagnosis 
of CAH (Table 1). 
To further confirm CAH diagnosis, a genomic 
analysis was performed from the DNA of the periphe-
ral blood leukocytes and the patient was found to be 
a compound heterozygous carrier of the Q318X and 
intron2 splicing (Sp2) mutation in the CYP21A2 gene. 
Later on, therapy was initiated with 5 mg of prednisone 
and 0.1 mg of fludrocortisone daily, with the androste-
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figure 1. Axial CT image (a), axial MR T2-weighted image (b), and in-
phase (c) and out-of-phase (D) T1-weighted images show a large 
heterogeneous left adrenal soft tissue mass (arrowheads; a, b and c) with 
substantial amount of interweaving free fat tissue (*; b). The free fat tissue 
is seen as low CT density (a) and low MR intensity (b and c) areas within 
the lesion. There is also a 1.5 cm nodule with similar features in the right 
gland (white arrow; a and D). 
figure 2. a. The gross pathology features of the left adrenal tumor show a 
yellowish to tan extradrenal mass that has grown beside the gland. b. The 
photomicrography shows the myelolipoma with mature adipose cells 
intermingled with the benign and cellular haematopoietic component (right 
side) that lies over a hyperplasic adrenal gland (left side). c. The 
photomicrography illustrates the micronodular pattern of the adrenocortical 
hyperplasia. D. A high-power field of the myelolipoma showing all 
haematopoietic lineages in maturation between the adipose cells. The arrow 
shows a normal megakaryocytic cell.
Discussion
The pathogenesis of adrenal myelolipomas remains 
unclear. A variety of mechanisms are proposed to un-
derlie the etiology of adrenal myelolipomas, such as 
the presence of embryonic bone marrow in adrenal 
tissue (3). Some evidences indicate that ACTH may 
have a role in the development of these tumors, de-
monstrated by an increase in the relative frequency 
of myelolipomas in patients with excessive ACTH 
secretion, such as in CAH (13,14), Nelson’s syn-
drome (15), and Addison’s disease (3). Moreover, 
myeloid metaplasia in the adrenal cortex is observed 
in severely burned and cancer patients, two groups 
that are subject to long periods of intense stress (16). 
Indeed, myelolipomas have been associated with various 
forms of CAH like 21OH deficiency, 17-hydroxylase 
(17OH) deficiency and recently with 11β-hydroxylase 
deficiency (17). It is worth pointing out that most of 
these patients were either untreated or had stopped 
taking their medication for an extended period and 
were exposed for many years to chronically elevated 
ACTH and androgen levels which have been shown 
to induce transformation of adrenal cortical precursor 
cells into mature fat cells (17,18).
To date, approximately 25 cases of myelolipomas as-
sociated with CAH have been reported. The mean age 
of these patients was 48 years (range 23-82 years). The 
characteristics of each patient and tumor are shown in 
table 2. The majority of them, 19 (76%), was associated 
with CAH due to 21OH deficiency, 4 (16%) with CAH 
due 17OH deficiency and 1 (4%) with CAH due to 
11β-hydroxylase deficiency. Our patient presents CAH 
due to 21OH deficiency, with a genotype Q318X / 
Sp2. Considering size and localization, the mean tumor 
size was 12.4 cm (range 1-43 cm) and bilateral lesions 
were reported in ten cases (40%). Jaresch and cols. (37) 
previously described a positive correlation between the 
age of CAH patients and the age at onset of therapy, 
and adrenal size; with older patients and patients who 
were untreated for a long period presenting the most 
hyperplastic adrenal glands with no correlation between 
tumor size and serum 17OHP concentrations. In the-
se cases, chronic ACTH excess could induce diffuse or 
nodular adrenocortical hyperplasia which would later 
become autonomous because of oncogenic mutations 
in the tissue. Although under-diagnosis of CAH due to 
21OH deficiency is more frequent in male patients, as 
observed in our case, there was no difference in gender 
prevalence of myelolipomas associated with CAH des-
nedione level falling into normal range (Table 1). A low 
testosterone level (3.2 nmol/L) and slightly high le-
vels of LH and FSH (20 and 13.2 IU/L, respectively), 
indicate an actual primary gonadal dysfunction most 
likely due to long-term suppression of hypothalamic-
pituitary-gonadal axis. 
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Table 1. Basal hormone concentrations before, after surgery and under treatment with prednisone (5 mg daily) associated with fludrocortisone (0.1 mg 
daily). Dexamethasone suppression test and ACTH1-24 stimulation test performed after surgery 
before 
surgery
after  
surgery
before
dexa
after  
dexa
acTH1-24 
basal
acTH1-24 after
60 min
under 
treatment
DHEA-S [6.5-9.1 mmol/L] 3.9 1.9 4.6 0.5 _ _ 0.2
Testosterone [8.7-31.2 nmol/L] 13.4 10.7 13.5 0.7 _ _ 3.2
Androstenedione [2.1-8.7 nmol/L] 74 25.5 24.6 0.5 _ _ 4.9
Cortisol [138-552 nmol/L] 154 _ _ _ 231 259.3 _
17OHP [0.9-6 nmol/L] 218 _ _ _ 261 342.5 _
17OHP: 17α-hydroxyprogesterone; dexa: dexamethasone; normal range in brackets. The dexamethasone test was performed with 2 mg/day dexamethasone during 5 days at 40 days post surgery. The 
ACTH1-24 test was performed with 25 ug ACTH at 35 days post surgery. 
Table 2. Reported cases of adrenal myelolipoma associated with congenital adrenal hyperplasia (CAH)
author year caH age (years) Gender adrenal presentation size (cm)
Schindler (19) 1975 21OH 53 F ND ND
Boudreaux and cols. (20) 1979 21OH 57 M Unilateral 34
Barr and Giltman (21) 1982 21OH 82 F Unilateral 400 g
Condom and cols. (22) 1985 17OH 50 F Unilateral 15
Sasano and cols. (23) 1987 17OH 31 M Unilateral 1
Sasano and cols. (23) 1987 17OH 39 F Bilateral Microscopy
Oliva and cols. (14) 1988 21OH 34 F Unilateral 13
Miyazaki and cols. (13) 1990 21OH 65 F Unilateral 5
Murakami and cols. (24) 1992 21OH 41 M Unilateral 3
Iwamoto and cols. (25) 1993 21OH 32 M Bilateral 4 and 5
Ravichandran and cols. (26) 1996 21OH 51 M Unilateral 11
Ravichandran and cols. (26) 1996 21OH 58 M Bilateral 2 and 10
Umpierrez and cols. (27) 1997 21OH 47 M Bilateral 5 and 2.5
Parenteau and cols. (28) 2000 21OH 28 M Unilateral 14
Nagai and cols. (29) 2001 17OH 45 F Unilateral 10
Allison and cols. (30) 2003 21OH 43 F Multi and bilateral 43; 8 and 24
Mathew and cols. (31) 2005 21OH 62 F Bilateral 12 and 6
Patocs and cols. (32) 2005 17OH 37 F Unilateral 7
Kalidindi and cols. (33) 2006 21OH 42 M Bilateral 25 and 23
Treska and cols. (34) 2006 21OH 56 F Bilateral 16 and 9
Sakaki and cols. (35) 2006 21OH 69 F Bilateral 8 and 4
Nigawara and cols. (36) 2008 21OH 66 M Unilateral 3.5
Hagiwara and cols. (8) 2008 21OH 43 F Unilateral 17
John and cols. (17) 2009 11beta 23 M Unilateral 10
Present case 2009 21OH 57 M Bilateral 10 and 1.5
Type of CAH: 21-hydroxylase deficiency (21OH); 17-hydroxilase deficiency (17OH); ND: not described.
cribed thus far in the literature, with 13 women and 12 
men accounting for the casuistics. The great majority 
of myelolipomas associated with CAH are localized in 
the adrenal gland, however there are descriptions of 
myelolipomas in other locations, such as the testis (38). 
There was also an increase in reports of myelolipomas 
in more recent years (12 reports in the last decade ver-
sus 13 from 1975 to 1997) explained by the widespread 
use of radiologic evaluation resulting in more diagnosis 
of adrenal incidentalomas (39). 
Myelolipoma associated with 21-hydroxylase deficiency
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In conclusion, we describe a rare case of giant mye-
lolipoma associated to CAH due to 21OH deficiency. 
The excessive ACTH and/or androgen secretion over 
a long period of time could have had a stimulatory role 
in the development of the adrenal myelolipoma in the 
present patient. However, the mechanism underlying 
the reduced 21OH reserve among incidentaloma pa-
tients and the increased occurrence of adrenal tumors 
in simple virilizing or late-onset CAH forms remains 
a matter of speculation. Additionally, although surgery 
was mandatory in the present case due to tumor symp-
toms and size, CAH should always be ruled out in in-
cidentally detected adrenal masses to avoid unnecessary 
surgical procedures. 
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